ワクチン受託製造の世界市場レポート 2025年

ワクチン受託製造市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.8％で59億3,000万米ドルに成長します。予測期間の成長は、パンデミック対策への重点の高まり、医薬品製造におけるアウトソーシングの増加、バイオ医薬品企業の拡大、ワクチン開発スケジュールの前倒し、ワクチン入手のための世界の取り組みなどに起因しています。予測期間における主な動向としては、製造におけるシングルユース技術の統合、ワクチン開発における個別化医療アプローチの台頭、mRNAワクチンやウイルスベクターワクチンの開発、連続製造プロセスの採用、充填仕上げサービスの拡大などが挙げられます。

予防接種を促進するイニシアチブの増加が予想されることから、ワクチン受託製造市場の今後の成長が見込まれます。ワクチン接種は、免疫システムを強化し、身体の防御を強化することにより、伝染病から身を守るための簡単で安全かつ効果的な方法として機能します。ワクチン受託製造をサポートする様々なワクチン製造プロセスの進歩や強化は、ワクチン接種を支持するイニシアチブの増加とともに期待されています。その一例として、米国保健社会福祉省は2022年11月、HRSA（保健資源サービス局）が支援する医療施設に対し、特に社会的に疎外された地域社会におけるCOVID-19ワクチンの入手可能性を高めるため、新たに3億5,000万米ドルのイニシアチブを発表しました。このように、ワクチン接種を支援するイニシアチブの急増は、ワクチン受託製造市場の成長の起爆剤となっています。

世界の感染症の流行増加は、ワクチン受託製造市場の成長を促進すると予想されます。感染症は、細菌、ウイルス、真菌、寄生虫などの病原性微生物によって引き起こされる疾患です。インフルエンザ、麻疹、新興ウイルスなどの感染症が発生すると、さらなる蔓延を防ぐためにワクチンの緊急需要が発生します。受託製造業者は、このような緊急のニーズに応えるため、生産量を迅速に拡大することができます。例えば、2022年12月、英国の国家統計機関であるOffice for National Statisticsのデータによると、感染率は35歳から69歳の間で上昇し、12歳から24歳の学齢期でも上昇しました。イングランドにおけるCOVID-19確定患者の総入院率は人口10万人当たり9.56人に上昇し、ICUおよび高依存性病棟の入院は人口10万人当たり0.29人に増加しました。さらに、2024年8月、英国健康安全保障局は、2023年のイングランドにおける麻疹患者数を368人と報告し、2022年の53人から7倍近く増加し、ウェストミッドランズとロンドンがそれぞれ44％と33％を占めました。したがって、世界の感染症の増加がワクチン受託製造市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ワクチン受託製造PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のワクチン受託製造市場：成長率分析
• 世界のワクチン受託製造市場の実績：規模と成長, 2019-2024
• 世界のワクチン受託製造市場の予測：規模と成長, 2024-2029, 2034F
• 世界ワクチン受託製造総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のワクチン受託製造市場：サービスタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 充填仕上げ
• バルク製品
• 世界のワクチン受託製造市場ワクチンの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 不活化ワクチン
• 生弱毒化ワクチン
• RNA（リボ核酸）ワクチン
• サブユニットワクチン
• トキソイドベースのワクチン
• 世界のワクチン受託製造市場：プロセス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 下流
• 上流
• 世界のワクチン受託製造市場事業規模別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前臨床
• 臨床
• 商業用
• 世界のワクチン受託製造市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 人間への使用
• 獣医
• 世界のワクチン受託製造市場、充填仕上げのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 無菌充填・仕上げ
• 凍結乾燥
• バイアル充填
• 注射器充填
• 世界のワクチン受託製造市場バルク製品のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細胞培養
• 微生物発酵
• 抗原産生
• バッファの準備

第7章 地域別・国別分析

• 世界のワクチン受託製造市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のワクチン受託製造市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ワクチン受託製造市場：競合情勢
• ワクチン受託製造市場：企業プロファイル
  • Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck KGaA
• Fujifilm Holdings Corporation
• Moderna
• BioNTech
• GSK Vaccines
• AstraZeneca PLC
• Ajinomoto Co. Inc.
• Icon plc
• Lonza Group AG
• Cytiva
• Catalent Inc.
• Charles River Laboratories International Inc.
• Serum Institute of India Pvt. Ltd
• Samsung Biologics
• WuXi Biologics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ワクチン受託製造市場2029：新たな機会を提供する国
• ワクチン受託製造市場2029：新たな機会を提供するセグメント
• ワクチン受託製造市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Vaccine contract manufacturing involves an arrangement where outside producers are engaged to create vaccines, overseeing the production, packing, and labeling of vaccines based on the specifications and demands of the contracting business or organization. The primary benefit of vaccine contract manufacturing is the simplification of production, resulting in cost savings and fewer operational challenges.

The main types of services involved in vaccine contract manufacturing include fill-finish and bulk products. Fill-finish specifically pertains to the filling and finishing stages of the vaccine manufacturing process. In the pharmaceutical industry, finishing involves the sterilization and standardization of vaccine components into containers, while filling refers to adding them to containers and sealing them properly. The vaccines produced through this process include inactivated vaccines, live-attenuated vaccines, RNA (ribonucleic acid) vaccines, subunit vaccines, and toxoid-based vaccines. These vaccines are prepared through downstream and upstream processes on preclinical, clinical, and commercial scales of operation, catering to both human use and veterinary end-users.

The vaccine contract manufacturing research report is one of a series of new reports from The Business Research Company that provides vaccine contract manufacturing market statistics, including the vaccine contract manufacturing industry's global market size, regional shares, competitors with vaccine contract manufacturing market share, detailed vaccine contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the vaccine contract manufacturing industry. This vaccine contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vaccine contract manufacturing market size has grown strongly in recent years. It will grow from $3.58 billion in 2024 to $3.93 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to traditional vaccine manufacturing limitations, global disease outbreaks driving vaccine demand, regulatory support for contract manufacturing, increasing complexity of vaccine production, and surge in vaccine research and development

The vaccine contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $5.93 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to growing emphasis on pandemic preparedness, increased outsourcing in pharmaceutical manufacturing, expansion of biopharmaceutical companies, accelerated vaccine development timelines, global initiatives for vaccine accessibility. Major trends in the forecast period include integration of single-use technologies in manufacturing, rise in personalized medicine approaches to vaccine development, development of mRNA and viral vector vaccines, adoption of continuous manufacturing processes, expansion of fill-finish services.

The anticipated rise in initiatives promoting vaccinations is set to drive the growth of the vaccine contract manufacturing market in the future. Vaccination serves as an easy, safe, and effective method to defend against contagious diseases by enhancing the immune system and fortifying the body's defenses. The advancement and enhancement of various vaccine manufacturing processes to support vaccine contract manufacturing are expected with increasing initiatives favoring vaccinations. An illustrative example is the U.S. Department of Health and Human Services' announcement in November 2022 of a new $350 million initiative for HRSA (Health Resources and Services Administration)-supported health facilities to enhance COVID-19 vaccine availability, particularly for marginalized communities. Thus, the surge in initiatives supporting vaccinations is a catalyst for the growth of the vaccine contract manufacturing market.

The increasing prevalence of infectious diseases globally is expected to drive the growth of the vaccine contract manufacturing market. Infectious diseases are disorders caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. When outbreaks of infectious diseases occur, such as influenza, measles, or emerging viruses, there is an urgent demand for vaccines to prevent further spread. Contract manufacturers can rapidly scale up production to meet these urgent needs. For instance, in December 2022, data from the Office for National Statistics, a UK-based national statistics institute, indicated that infection rates rose among individuals aged 35 to 69 and also increased for those in school years 12 to 24. The total hospital admission rate for confirmed COVID-19 patients in England rose to 9.56 per 100,000 individuals, with ICU and high dependency unit admissions increasing to 0.29 per 100,000 inhabitants. Additionally, in August 2024, the UK Health Security Agency reported 368 measles cases in England for 2023, nearly a sevenfold increase from the 53 cases in 2022, with the West Midlands and London accounting for 44% and 33% of the cases, respectively. Therefore, the rise in infectious diseases worldwide is driving the growth of the vaccine contract manufacturing market.

Strategic partnerships are a prominent trend gaining traction in the vaccine contract manufacturing market. Major companies are collaborating with entities in this sector to strengthen their market positions. For example, in January 2023, Vaxxas, an Australia-based biotechnology firm known for its innovative needle-free vaccination technology, joined forces with the Coalition for Epidemic Preparedness Innovations, a Norway-based foundation, to finance and coordinate the development of new vaccines and advance Vaxxas' needle-free vaccine patch delivery technology. This initiative aims to eliminate the need for frozen storage for mRNA vaccines. Additionally, in October 2024, LenioBio, a Germany-based biotech company, partnered with ReciBioPharm, a US-based contract development and manufacturing organization (CDMO), to enhance its protein manufacturing capabilities and expedite vaccine production. This partnership supports LenioBio's strategy to broaden the scope of its CEPI-funded project, which seeks to showcase the speed and efficiency of its proprietary ALiCE protein expression technology in producing vaccine-related proteins for clinical trials.

Major companies in the vaccine contract manufacturing market are directing their efforts toward establishing production sites dedicated to vaccine contract manufacturing. This entails creating facilities exclusively for the manufacturing and production of vaccines on a contractual basis. WuXi Vaccines, a China-based contract development and manufacturing organization (CDMO), expanded its capabilities with the opening of its first standalone vaccine CDMO site in Suzhou, China, in September 2023. This expansion enhances WuXi Vaccines' capacity to contribute to vaccine development and manufacturing, reinforcing its pivotal role in advancing global healthcare solutions.

In October 2024, SK bioscience, a South Korea-based vaccine and biotech firm, acquired a controlling stake in IDT Biologika for approximately $244 million. This acquisition is part of SK bioscience's strategy to accelerate growth, with a goal of achieving consolidated sales of KRW 1 trillion (around USD 757.6 million) within the next five years. The company also intends to expand further by launching next-generation pneumococcal vaccines, positioning itself for continued financial growth beyond 2028. IDT Biologika is a German-based company that operates as a vaccine contract development and manufacturing organization (CDMO).

Major companies operating in the vaccine contract manufacturing market include Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Fujifilm Holdings Corporation, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Icon plc, Lonza Group AG, Cytiva, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Albany Molecular Research Inc., Soligenix Inc., Bio Farma, Curia Global Inc., Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

North America was the largest region in the vaccine contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in the vaccine contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vaccine contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vaccine contract manufacturing market consists of revenues earned by entities by providing services such as analytical, quality control studies, cell or virus banking, and cold chain services. The market value includes the value of related goods sold by the service provider or included within the service offering. The vaccine contract manufacturing market also includes sales of synthetic vaccines and DNA (deoxyribonucleic acid) vaccines, which are used in providing vaccine contract manufacturing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vaccine Contract Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vaccine contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vaccine contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vaccine contract manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Service Type: Fill-Finish; Bulk Product
• 2) By Vaccine Type: Inactivated Vaccines; Live-Attenuated Vaccines; RNA (Ribonucleic Acid) Vaccines; Subunit Vaccines; Toxoid-Based Vaccines
• 3) By Process: Downstream; Upstream
• 4) By Scale Of Operation: Preclinical; Clinical; Commercial
• 5) By End-Use: Human Use; Veterinary
• Subsegments:
• 1) By Fill-Finish: Aseptic Fill-Finish; Lyophilization; Vial Filling; Syringe Filling
• 2) By Bulk Product: Cell Culture; Microbial Fermentation; Antigen Production; Buffer Preparation
• Companies Mentioned: Pfizer Inc; Johnson & Johnson; AbbVie Inc.; Sanofi; GlaxoSmithKline
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vaccine Contract Manufacturing Market Characteristics

3. Vaccine Contract Manufacturing Market Trends And Strategies

4. Vaccine Contract Manufacturing Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Vaccine Contract Manufacturing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vaccine Contract Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vaccine Contract Manufacturing Market Growth Rate Analysis
• 5.4. Global Vaccine Contract Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vaccine Contract Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vaccine Contract Manufacturing Total Addressable Market (TAM)

6. Vaccine Contract Manufacturing Market Segmentation

• 6.1. Global Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fill-Finish
• Bulk Product
• 6.2. Global Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Vaccines
• Live-Attenuated Vaccines
• RNA (Ribonucleic Acid) Vaccines
• Subunit Vaccines
• Toxoid-Based Vaccines
• 6.3. Global Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Downstream
• Upstream
• 6.4. Global Vaccine Contract Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preclinical
• Clinical
• Commercial
• 6.5. Global Vaccine Contract Manufacturing Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Use
• Veterinary
• 6.6. Global Vaccine Contract Manufacturing Market, Sub-Segmentation Of Fill-Finish, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aseptic Fill-Finish
• Lyophilization
• Vial Filling
• Syringe Filling
• 6.7. Global Vaccine Contract Manufacturing Market, Sub-Segmentation Of Bulk Product, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cell Culture
• Microbial Fermentation
• Antigen Production
• Buffer Preparation

7. Vaccine Contract Manufacturing Market Regional And Country Analysis

• 7.1. Global Vaccine Contract Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vaccine Contract Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vaccine Contract Manufacturing Market

• 8.1. Asia-Pacific Vaccine Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vaccine Contract Manufacturing Market

• 9.1. China Vaccine Contract Manufacturing Market Overview
• 9.2. China Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vaccine Contract Manufacturing Market

• 10.1. India Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vaccine Contract Manufacturing Market

• 11.1. Japan Vaccine Contract Manufacturing Market Overview
• 11.2. Japan Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vaccine Contract Manufacturing Market

• 12.1. Australia Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vaccine Contract Manufacturing Market

• 13.1. Indonesia Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vaccine Contract Manufacturing Market

• 14.1. South Korea Vaccine Contract Manufacturing Market Overview
• 14.2. South Korea Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vaccine Contract Manufacturing Market

• 15.1. Western Europe Vaccine Contract Manufacturing Market Overview
• 15.2. Western Europe Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vaccine Contract Manufacturing Market

• 16.1. UK Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vaccine Contract Manufacturing Market

• 17.1. Germany Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vaccine Contract Manufacturing Market

• 18.1. France Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vaccine Contract Manufacturing Market

• 19.1. Italy Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vaccine Contract Manufacturing Market

• 20.1. Spain Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vaccine Contract Manufacturing Market

• 21.1. Eastern Europe Vaccine Contract Manufacturing Market Overview
• 21.2. Eastern Europe Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vaccine Contract Manufacturing Market

• 22.1. Russia Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vaccine Contract Manufacturing Market

• 23.1. North America Vaccine Contract Manufacturing Market Overview
• 23.2. North America Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vaccine Contract Manufacturing Market

• 24.1. USA Vaccine Contract Manufacturing Market Overview
• 24.2. USA Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vaccine Contract Manufacturing Market

• 25.1. Canada Vaccine Contract Manufacturing Market Overview
• 25.2. Canada Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vaccine Contract Manufacturing Market

• 26.1. South America Vaccine Contract Manufacturing Market Overview
• 26.2. South America Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vaccine Contract Manufacturing Market

• 27.1. Brazil Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vaccine Contract Manufacturing Market

• 28.1. Middle East Vaccine Contract Manufacturing Market Overview
• 28.2. Middle East Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vaccine Contract Manufacturing Market

• 29.1. Africa Vaccine Contract Manufacturing Market Overview
• 29.2. Africa Vaccine Contract Manufacturing Market, Segmentation By Service Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vaccine Contract Manufacturing Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vaccine Contract Manufacturing Market, Segmentation By Process, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vaccine Contract Manufacturing Market Competitive Landscape And Company Profiles

• 30.1. Vaccine Contract Manufacturing Market Competitive Landscape
• 30.2. Vaccine Contract Manufacturing Market Company Profiles
  • 30.2.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline Overview, Products and Services, Strategy and Financial Analysis

31. Vaccine Contract Manufacturing Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. Fujifilm Holdings Corporation
• 31.3. Moderna
• 31.4. BioNTech
• 31.5. GSK Vaccines
• 31.6. AstraZeneca PLC
• 31.7. Ajinomoto Co. Inc.
• 31.8. Icon plc
• 31.9. Lonza Group AG
• 31.10. Cytiva
• 31.11. Catalent Inc.
• 31.12. Charles River Laboratories International Inc.
• 31.13. Serum Institute of India Pvt. Ltd
• 31.14. Samsung Biologics
• 31.15. WuXi Biologics

32. Global Vaccine Contract Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vaccine Contract Manufacturing Market

34. Recent Developments In The Vaccine Contract Manufacturing Market

35. Vaccine Contract Manufacturing Market High Potential Countries, Segments and Strategies

• 35.1 Vaccine Contract Manufacturing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vaccine Contract Manufacturing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vaccine Contract Manufacturing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer